The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Breast cancer statistics, 2019
Open accessAbstract
This article is the American Cancer Society’s biennial update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Over the most recent 5‐year period (2012‐2016), the breast cancer incidence rate increased slightly by 0.3% per year, largely because of rising rates of local stage and hormone receptor‐positive disease. In contrast, the breast cancer death rate continues to decline, dropping 40% from 1989 to 2017 and translating to 375,900 breast cancer deaths averted. Notably, the pace of the decline has slowed from an annual decrease of 1.9% during 1998 through 2011 to 1.3% during 2011 through 2017, largely driven by the trend in white women. Consequently, the black–white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades. Nevertheless, the death rate remains 40% higher in blacks (28.4 vs 20.3 deaths per 100,000) despite a lower incidence rate (126.7 vs 130.8); this disparity is magnified among black women aged <50 years, who have a death rate double that of whites. In the most recent 5‐year period (2013‐2017), the death rate declined in Hispanics (2.1% per year), blacks (1.5%), whites (1.0%), and Asians/Pacific Islanders (0.8%) but was stable in American Indians/Alaska Natives. However, by state, breast cancer mortality rates are no longer declining in Nebraska overall; in Colorado and Wisconsin in black women; and in Nebraska, Texas, and Virginia in white women. Breast cancer was the leading cause of cancer death in women (surpassing lung cancer) in four Southern and two Midwestern states among blacks and in Utah among whites during 2016‐2017. Declines in breast cancer mortality could be accelerated by expanding access to high‐quality prevention, early detection, and treatment services to all women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Self-citationSiegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Self-citationWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Self-citationBreast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Self-citationScreening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2771 · Cited by 2,632
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,460
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force (2016) · Annals of Internal Medicine · doi:10.7326/m15-2886 · Cited by 2,094
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Oeffinger, K. C., Fontham, E. T. H., Etzioni, R., Herzig, A., Michaelson, J. S., Shih, Y.-C. T., Walter, L. C., Church, T. R., Flowers, C. R., LaMonte, S. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.12783 · Cited by 1,653
Self-citationThe Decrease in Breast-Cancer Incidence in 2003 in the United States
Ravdin, P. M., Cronin, K. A., Howlader, N., Berg, C. D., Chlebowski, R. T., Feuer, E. J., Edwards, B. K., & Berry, D. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr070105 · Cited by 982
Kohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Self-citationNationwide Trends in Mastectomy for Early-Stage Breast Cancer
Kummerow, K. L., Du, L., Penson, D. F., Shyr, Y., & Hooks, M. A. (2015) · JAMA Surgery · doi:10.1001/jamasurg.2014.2895 · Cited by 719
Iqbal, J., Ginsburg, O., Rochon, P. A., Sun, P., & Narod, S. A. (2015) · JAMA · doi:10.1001/jama.2014.17322 · Cited by 614
Differences in Breast Cancer Survival by Molecular Subtypes in the United States
Howlader, N., Cronin, K. A., Kurian, A. W., & Andridge, R. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0627 · Cited by 598
Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States
Mariotto, A. B., Etzioni, R., Hurlbert, M., Penberthy, L., & Mayer, M. (2017) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0889 · Cited by 529
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Esteva, F. J., Hubbard-Lucey, V. M., Tang, J., & Pusztai, L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30026-9 · Cited by 453
Cancer Incidence and Mortality Trends Among Whites in the United States, 1947–84
(1987) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/79.4.701 · Cited by 450
Singh, G. K., & Hiatt, R. A. (2006) · International Journal of Epidemiology · doi:10.1093/ije/dyl089 · Cited by 448
Mallin, K., Browner, A., Palis, B., Gay, G., McCabe, R., Nogueira, L., Yabroff, R., Shulman, L., Facktor, M., Winchester, D. P., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07213-1 · Cited by 396
Effect of Screening and Adjuvant Therapy on Mortality From Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000201966.23445.91 · Cited by 386
Daly, B., & Olopade, O. I. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21271 · Cited by 327
McGuire, K. P., Santillan, A. A., Kaur, P., Meade, T., Parbhoo, J., Mathias, M., Shamehdi, C., Davis, M., Ramos, D., & Cox, C. E. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0635-x · Cited by 326
Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., Sledge, G. W., Mandelblatt, J. S., & Kurian, A. W. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky062 · Cited by 315
Health Disparities and Triple-Negative Breast Cancer in African American Women: A Review
Newman, L. A., & Kaljee, L. M. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.0005 · Cited by 304
Self-citationPlevritis, S. K., Munoz, D., Kurian, A. W., Stout, N. K., Alagoz, O., Near, A. M., Lee, S. J., van den Broek, J. J., Huang, X., Schechter, C. B., et al. (2018) · JAMA · doi:10.1001/jama.2017.19130 · Cited by 302
Incidence of Breast Cancer in the United States: Current and Future Trends
Anderson, W. F., Katki, H. A., & Rosenberg, P. S. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr257 · Cited by 285
Huo, D., Hu, H., Rhie, S. K., Gamazon, E. R., Cherniack, A. D., Liu, J., Yoshimatsu, T. F., Pitt, J. J., Hoadley, K. A., Troester, M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0595 · Cited by 283
Warner, E. T., Tamimi, R. M., Hughes, M. E., Ottesen, R. A., Wong, Y.-N., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1349 · Cited by 280
Changes in Mortality After Massachusetts Health Care Reform: A Quasi-experimental Study
Sommers, B. D., Long, S. K., & Baicker, K. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2275 · Cited by 222
Pfeiffer, R. M., Webb-Vargas, Y., Wheeler, W., & Gail, M. H. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-0098 · Cited by 178
Scott, L. C., Mobley, L. R., Kuo, T., & Il’yasova, D. (2019) · Cancer · doi:10.1002/cncr.32207 · Cited by 165
Breast Cancer Incidence Rates in U.S. Women Are No Longer Declining
DeSantis, C., Howlader, N., Cronin, K. A., & Jemal, A. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0061 · Cited by 159
Self-citationUpdate on mammography trends: Comparisons of rates in 2000, 2005, and 2008
Breen, N., Gentleman, J. F., & Schiller, J. S. (2011) · Cancer · doi:10.1002/cncr.25679 · Cited by 155
Hunt, B. R., Whitman, S., & Hurlbert, M. S. (2014) · Cancer Epidemiology · doi:10.1016/j.canep.2013.09.009 · Cited by 152
Albornoz, C. R., Matros, E., Lee, C. N., Hudis, C. A., Pusic, A. L., Elkin, E. B., Bach, P. B., Cordeiro, P. G., & Morrow, M. (2015) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000001276 · Cited by 150
Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality
Muñoz, D. F., Near, A. M., van Ravesteyn, N. T., Lee, S. J., Schechter, C. B., Alagöz, O., Berry, D. A., Burnside, E. S., Chang, Y.-J., Chisholm, G. B., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju289 · Cited by 146
Tao, L., Gomez, S. L., Keegan, T. H. M., Kurian, A. W., & Clarke, C. A. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0243 · Cited by 138
Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor Molecular Subtype
Gaudet, M. M., Gierach, G. L., Carter, B. D., Luo, J., Milne, R. L., Weiderpass, E., Giles, G. G., Tamimi, R. M., Eliassen, A. H., ROSNER, B. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0502 · Cited by 111
Self-citationPinheiro, P. S., Morris, C. R., Liu, L., Bungum, T. J., & Altekruse, S. F. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu016 · Cited by 103
Triple-Negative Breast Cancer: Current Practice and Future Directions
Costa, R. L. B., & Gradishar, W. J. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.023333 · Cited by 100
Racial/Ethnic Disparities in Time to a Breast Cancer Diagnosis
Molina, Y., Silva, A., & Rauscher, G. H. (2015) · Medical Care · doi:10.1097/mlr.0000000000000417 · Cited by 92
Nash, R., Goodman, M. G., Lin, C. C., Freedman, R. A., Dominici, L. S., Ward, K. C., & Jemal, A. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.0115 · Cited by 91
Self-citationJohn, E. M., Hines, L. M., Phipps, A. I., Koo, J., Longacre, T. A., Ingles, S. A., Baumgartner, K. B., Slattery, M. L., & Wu, A. H. (2018) · International Journal of Cancer · doi:10.1002/ijc.31258 · Cited by 81
Hunt, B. R., & Hurlbert, M. S. (2016) · Cancer Epidemiology · doi:10.1016/j.canep.2016.07.018 · Cited by 61
Warnecke, R. B., Campbell, R. T., Vijayasiri, G., Barrett, R. E., & Rauscher, G. H. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0945 · Cited by 58
The impact of changes in hormone therapy on breast cancer incidence in the US population
Coombs, N. J., Cronin, K. A., Taylor, R. J., Freedman, A. N., & Boyages, J. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9437-5 · Cited by 54
Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California
Parise, C. A., & Caggiano, V. (2014) · Cancer Epidemiology · doi:10.1016/j.canep.2014.08.001 · Cited by 52
Sung, H., DeSantis, C., Fedewa, S., Kantelhardt, E., & Jemal, A. (2019) · Cancer · doi:10.1002/cncr.32293 · Cited by 45
Self-citationReceipt of locoregional therapy among young women with breast cancer
Freedman, R. A., Virgo, K. S., Labadie, J., He, Y., Partridge, A. H., & Keating, N. L. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2156-8 · Cited by 41
Trends in stage at diagnosis for young breast cancer patients in the United States
Desantis, C. E., Ma, J., & Jemal, A. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5042-1 · Cited by 38
Self-citationHines, L. M., Sedjo, R. L., Byers, T., John, E. M., Fejerman, L., Stern, M. C., Baumgartner, K. B., Giuliano, A. R., Torres-Mejı́a, G., Wolff, R. K., et al. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0721 · Cited by 24
Parsing the Etiology of Breast Cancer Disparities
Newman, L. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.1877 · Cited by 18
Self-citation
Research works printed but not linked: 16
- Surveillance, Epidemiology, and End Results (SEER) Program, 2019, SEER*Stat Database: Incidence‐SEER 9 Regs Research Data with Delay‐Adjustment, Malignant Only, based on the November 2018 submission
- Surveillance Epidemiology and End Results (SEER) Program.Breast Schema for 1988‐2015 Based on AJCC 6th Edition. Accessed August 8 2019.seer.cancer.gov/seerstat/variables/seer/ajcc-stage/6th/breast.html
- Surveillance, Epidemiology, and End Results (SEER) Program, 2019, SEER*Stat Database: Incidence‐SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2018 Submission (2000‐2016) <Katrina/Rita Population Adjustment>‐Linked To County Attributes‐Total U.S., 1969‐2017 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2018, SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data‐Cancer in North America (CiNA) Analytic File, 1995‐2015, for NHIAv2 Origin, Custom File With County, American Cancer Society (ACS) Facts and Figures Projection Project (which includes data from the Centers for Disease and Prevention's [CDC's] National Program of Cancer Registries [NPCR], the Canadian Council of Cancer Registry's [CCCR's] Provincial and Territorial Registries, and the National Cancer Institute's [NCI's] SEER Registries)
- Surveillance, Epidemiology, and End Results (SEER) Program, 2018, SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data‐Cancer in North America (CiNA) Analytic File, 1995‐2016, for Expanded Races, Custom File With County, American Cancer Society (ACS) Facts and Figures Projection Project (which includes data from the Centers for Disease and Prevention's [CDC's] National Program of Cancer Registries [NPCR], the Canadian Council of Cancer Registry's [CCCR's] Provincial and Territorial Registries, and the National Cancer Institute's [NCI's] SEER Registries)
- Surveillance, Epidemiology, and End Results (SEER) Program (seer.cancer.gov), SEER*Stat Database: Mortality ‐ All COD, Total U.S. (1969‐2017) <Early release with Vintage 2017 Katrina/Rita Population Adjustment> ‐ Linked To County Attributes ‐ Total U.S., 1969‐2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released May 2019. Underlying mortality data provided by NCHS (cdc.gov/nchs)
- Surveillance, Epidemiology, and End Results (SEER) Program, 2019, SEER*Stat Database: Mortality‐All COD, Aggregated With State, Total U.S. (1990‐2017) <Early release with Vintage 2017 Katrina/Rita Population Adjustment>
- American College of Surgeons Commission on Cancer, 2019, National Cancer Database, 2016 Data Submission
- Centers for Disease Control and Prevention, 2016, Behavioral Risk Factor Surveillance System Survey Data 2016
- Surveillance Research Program, National Cancer Institute, 2018, SEER*Stat Software. Version 8.3.5
- National Cancer Institute, 2019, Joinpoint Regression Program, Version 4.7.0.0
- National Cancer Institute, 2019, DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.7
- Howlader N, 2019, SEER Cancer Statistics Review, 1975‐2016. Based on the November 2018 SEER data submission, posted to the SEER website April 2019
- 10.1158/1055-9965.EPI-14-0624 · doi:10.1158/1055-9965.epi-14-0624
- Martin JA, 2018, Births: Final Data for 2017, Natl Vital Stat Rep., 67, 1
- 10.1245/s10434-018-6531-5 · doi:10.1245/s10434-018-6531-5
Cited by
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Self-citationSiegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Self-citationCurrent and future burden of breast cancer: Global statistics for 2020 and 2040
Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.08.010 · Cited by 3,411
“Rising incidence rates have been reported in several high-income countries in North America, Europe and Oceania since 2007 for pre- and postmenopausal breast cancer [2,20].”
BackgroundLoibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Estimated Projection of US Cancer Incidence and Death to 2040
Rahib, L., Wehner, M. R., Matrisian, L. M., & Nead, K. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.4708 · Cited by 1,339
Metadata
- Authors
- DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2019-10-02
- Volume
- 69
- Issue
- 6
- Pages
- 438-451
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W2979291688
- Cited by
- 3,114
- References
- 57
- FWCI
- 170.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.